key: cord-0884526-zwg3u93u authors: Chung, Jee Young; Thone, Melissa N.; Kwon, Young Jik title: COVID-19 vaccines: The status and perspectives in delivery points of view date: 2020-12-24 journal: Adv Drug Deliv Rev DOI: 10.1016/j.addr.2020.12.011 sha: dd1fae0608a68a8b655e1e1ee2e73653f8048408 doc_id: 884526 cord_uid: zwg3u93u Due to the high prevalence and long incubation periods often without symptoms, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals globally, causing the coronavirus disease 2019 (COVID-19) pandemic. Even with the recent approval of the anti-viral drug, remdesivir, and Emergency Use Authorization of monoclonal antibodies against S protein, bamlanivimab and casirimab/imdevimab, efficient and safe COVID-19 vaccines are still desperately demanded not only to prevent its spread but also to restore social and economic activities via generating mass immunization. Recent Emergency Use Authorization of Pfizer and BioNTech’s mRNA vaccine may provide a pathway forward, but monitoring of long-term immunity is still required, and diverse candidates are still under development. As the knowledge of SARS-CoV-2 pathogenesis and interactions with the immune system continues to evolve, a variety of drug candidates are under investigation and in clinical trials. Potential vaccines and therapeutics against COVID-19 include repurposed drugs, monoclonal antibodies, antiviral and antigenic proteins, peptides, and genetically engineered viruses. This paper reviews virology and immunology of SARS-CoV-2, alternative therapies for COVID-19 to vaccination, principles and design considerations in COVID-19 vaccine development, and the promises and roles of vaccine carriers in addressing the unique immunopathological challenges presented by the disease. viral clearance at early stages of infection, but a robust and persistent immune response can lead to massive cytokine production and damage to host tissues [102, 103] . Approximately 14% of COVID-19 patients become severely ill with dyspnea and difficulty breathing, and 5% enter critical conditions including respiratory failure, septic shock, and multiple organ dysfunction and failure [95] . The first autopsy of a COVID-19 patient revealed accumulation of mononuclear monocytes and inflammatory T cells in the lungs but with low levels of active T cells against SARS-CoV-2 [97] . In other severe COVID-19 cases, distinct profiles of cell populations have been observed [104] . Patients showed similar overall levels in total activated T cells and cytotoxic T lymphocytes (CTLs), particularly increased levels of CD4 + T cells, leukocytes, neutrophils, and decreased monocytes, eosinophils, basophils, Treg, memory and, CD8 + T cells [105, 106] . Additional studies found increased concentrations of IL-1β, IFN-γ [107] , and IL-6 [108, 109] . Upon recognition of a pathogenic antigen and recovery, a subset of memory T cells remain in the lungs [110] , ready for action upon secondary exposure or infection. Resident memory T cells were proven to be critical for viral clearance as a human respiratory syncytial virus (RSV) study showed that they could eradicate the virus without assistance of antibodies [111] . . Immune response to SARS-CoV-2 at varying pathological stages. In stage 1, in the nasal cavity, SARS-CoV-2 binds to ACE2 receptors on epithelial cells by the S protein, enters the cell, and starts to replicate. The virus proliferates and simultaneously travels down the respiratory tract, and clinical manifestation of symptoms start appearing. Upon infection, the virus activates type I IFNs. In COVID-19 patients, type 1 IFN production is delayed by SARS-CoV-2, which lowers the adaptive immune response. The host innate immune system detects SARS-CoV-2 via recognition of pathogen-associated molecular patterns (PAMPs) by the alveolar macrophages activating cytokines such IL-6 and TNF-α leading to phagocytosis of the virus or activation. In stage 2, infected epithelial cells present viral antigens to both CD4 + and CD8 + T cells. CD8 + T cells release perforins and granzymes that induce apoptosis of the infected cells. CD4 + T cells rapidly activate to become Th1 cells that secrete GM-CSF and further J o u r n a l P r e -p r o o f induce monocytes by high IL-6 levels. An increase in monocyte subpopulation promotes IL-1β production. Th17 cells produce IL-17 to further recruit monocytes, macrophages, and neutrophils, and stimulates other inflammatory cytokines such as IL-6, IL-1, and IL-1β. In stage 3, inflammatory cells release additional cytokines which amplifies the cytokine storm and exacerbates the systemic inflammatory response, eventually leading to ARDS, multiorgan failure, and death. The transition between innate and adaptive immune responses is crucial for controlling SARS-CoV-2 infection and is dependent on CD4 + T cells to interact with B cells to produce specific neutralizing antibodies [112] . Previous studies have reported specific neutralizing antibodies against the S protein [113] [114] [115] . However, there are still several questions regarding the significance of the antibodies to the viral protein and the cross-reactivity of antibodies to other prevalent coronaviruses, in particular between SARS-CoV and SARS-CoV-2, with 79.6% identical structural features [116, 117] . Antibody responses are detectable within 1-2 weeks after symptom onset in most infected individuals [118] . Specifically, IgM and IgA against SARS-CoV-2 have been detected within the 1st week of infection, while IgG antibodies have been detected around day 14 after the onset of symptoms [119] [120] [121] [122] . Recent studies indicate that neutralizing antibodies were closely correlated with the severity in COVID-19 patients [123] , and antibody responses faded within weeks after infection [124] . Furthermore, the neutralizing antibody response in asymptomatic individuals decreased faster and remained lower than in symptomatic individuals [125] . In the case of SARS-CoV, long lasting, specific IgG, and neutralizing antibodies were reported to last as long as 2 years after infection [126] , while MERS-CoV neutralizing antibodies were detected within 14-21 days of illness onset [127] . No correlation between protections from SARS-CoV-2 and other coronaviruses have been confirmed, and it is unknown what neutralizing antibody titers are necessary to provide full infection induces a massive release of cytokines including IL6, IL-1β, and IL-1 and increases the activation of NF-κB and JAK-STAT signaling pathways. Tocilizumab and sarilumab bind to membrane and soluble IL-6 receptors suppressing the JAK-STAT signaling pathway and attenuating inflammatory processes. Baricitinib and ruxolitinib inhibit the kinase activities of JAK1 and JAK2 and anakinra, an IL-1 receptor antagonist, reduces hyperinflammation and respiratory distress. [133, 134] . It terminates RNA synthesis and inhibits SARS-CoV-2 genome replication, which previously exhibited antiviral activities against SARS-CoV and MERS-CoV [135, 136] . Clinical trials of remdesivir on randomized, placebo-controlled, treatment groups with 1,062 patients improved the recovery time of some COVID-19 patients at advanced stages [137] . Favipiravir, a guanine analogue, inhibits RNA polymerase and is currently used for influenza treatment [138] . A combination of favipiravir and interferon-α (ChiCTR2000029600) or baloxavir marboxil (ChiCTR2000029544) showed anti-SARS-CoV activity in Vero E6 cells, and randomized clinical trials to evaluate their safety and efficacy are underway [139] . Other antivirals currently repurposed for COVID-19 therapy include neuraminidase inhibitor oseltamivir. Oseltamivir has been used for influenza A and B viruses as they require neuraminidase for virus release to host cells. SARS-CoV-2 does not express neuraminidase therefore combination therapy of oseltamivir together with protease inhibitors has shown efficacy [140, 141] . cells [149] , and is also being considered as a COVID-19 therapy in combination with protease inhibitors [151] . Well-known anti-malarial and anti-autoimmune agents, chloroquine, and hydroxychloroquine block viral infection by increasing endosomal pH to inhibit the membrane fusion between virus and host human cells [152, 153] . Hydroxychloroquine, a derivative of chloroquine, has similar pharmacokinetic effects to chloroquine with fewer side effects [154] . Hydroxychloroquine treatment showed viral clearance in COVID-19 patients and combination therapy with azithromycin elevated the anti-viral effect [155] . Additionally, a number of clinical trials in China showed marginal therapeutic efficacy of hydroxychloroquine in patients with COVID-19-induced pneumonia [156] . However, the FDA has warned about using chloroquine/hydroxychloroquine outside the hospital due to its serious arrhythmia risks in COVID-19 patients with a history of hypertension, heart failure, and chronic kidney diseases, rejecting approval for COVID-19 therapy [157] . Chloroquine treatment showed specific inhibition of SARS-CoV replication by interfering with the glycosylation of ACE2 receptor [153] , effectively reducing the copy number of SARS-CoV-2 [158] . Interestingly, ACE2 receptor inhibitors were shown to increase the expression of ACE2 receptors, resulting in enhanced viral entry, limiting their clinical benefits [159] . Several immune-modulating drugs that regulate inflammation are being tested for their efficacy for severe COVID-19 [160] . The cytokine storm is a critical determinant of mortality in patients with serious symptoms in the late stage of COVID-19 [103] . IL-6 is a key inflammatory J o u r n a l P r e -p r o o f cytokine which is highly elevated in severely ill COVID-19 patients [76, 161] and the IL6/IL-6 receptor (IL-6R) signaling pathway is a promising target for alleviated inflammatory symptoms. Tocilizumab, a humanized anti IL-6 receptor antibody, approved for used in rheumatoid arthritis [162] was shown to be effective against cytokine release syndrome associated with CAR-T cell therapy [163] . Tocilizumab binds to both membrane and soluble IL-6 receptors in suppressing the JAK-STAT signaling pathway and downregulating the downstream inflammatory molecules [164] . Administration of tocilizumab has shown improvement of respiratory function in COVID-19 patients within a few days [164] . Sarilumab, another IL-6 receptor blocker, also inhibits the IL-6 signaling pathway and a clinical trial is underway to evaluate its safety and efficacy in COVID-19 patients with serious complications [165] . Inhibition of JAK-STAT pathways using JAK inhibitors approved for rheumatoid arthritis and psoriatic arthritis therapy is another potential immunotherapeutic approach to alleviating the cytokine storm in COVID-19 [166] . Baricitinib inhibits the kinase activities of JAK1 and JAK2 and efficiently reduced SARS-CoV-2 viral infection [167] , and rituxolitinib, another JAK1 and JAK2 inhibitor, has shown some efficacy in reducing severe respiratory distress [168] . IL-1 was reported to be increased in some COVID-19 patients [5] and blocking IL-1 using anakinra, an IL-1 receptor antagonist previously approved for rheumatoid arthritis therapy, has shown promising results in reducing hyperinflammation and respiratory distress in COVID-19 patients (NCT04324021). Corticosteroids appear to be beneficial for critically ill COVID-19 patients according to a meta-analysis of seven randomized clinical trials that included 1,703 patients recruited from 5 different continents [169] . Steroids are cheap, readily available, and are effective in reducing deaths of the most severely affected COVID-19 patients [169] . Dexamethasone, an antiinflammatory drug, has anti-fibrotic and vasoconstrictive effects [170] and many clinical trials in J o u r n a l P r e -p r o o f Journal Pre-proof the past decade have tested its efficacy in treating pneumonia, sepsis, or ARDS [171] . In ARDS patients, corticosteroids improved oxygen saturation and reduced inflammation [172] . Since a recent trial showed dexamethasone reduced the death of ventilated COVID-19 patients by onethird [173] , steroids have been proposed as potential COVID-19 drugs, attributed to their ability to help dampen inflammation and other immune system responses [174] . Despite the benefit of calming the cytokine storm, suppressed inflammation and immune response impede viral clearance and prevention of viral spread. Natural Killer (NK) cells are innate immune responders and critical for viral clearance and immunomodulation. In addition to their antiviral activities, NK cells also play key immunopathological roles during the infections of RSV, influenza A virus, and hepatitis B virus [175] . A previous study showed that migration of NK cells and macrophages helped clear SARS-CoV [176] , and NK cells from COVID-19 patients showed increased perforin levels, providing a basis for understanding the role of NK cells in COVID-19 infections [177] . Given the importance of NK cells in acute viral infection, recent studies have demonstrated potential strategies for NK cell-based immunotherapy for COVID-19 [178] . An ongoing clinical trial in China investigates the use of NK cells for viral clearance in severe COVID-19-associated pneumonia patients (NCT04280224). Self-renewing, multi-potent mesenchymal stem cells (MSCs) also play an important role in inflammatory diseases with their anti-inflammatory properties [179] . MSCs have been shown to help alleviate the cytokine storm, repair pulmonary epithelial damage, and facilitate alveolar fluid clearance [180] . Animal studies using MSCs demonstrated a reduction of influenza A H5N1 acute lung injury [181] . Several phase I and II J o u r n a l P r e -p r o o f clinical trials have confirmed the safety and efficacy of MSC therapy for ARDS patients [182, 183] . Antibody-mediated humoral immunity is critical for the prevention of recurring viral infections, and neutralizing antibodies are specific and effective to target the virus. This classical adaptive prevention approach has been applied to many infectious diseases including SARS-CoV, MERS-CoV, and the H1N1 infections [184] . The SARS-CoV-2 S protein is the major inducer of neutralizing antibodies and monoclonal antibodies against it, bamlanivimab [185], casirivimab and imdevimab [186] were approved for emergency use authorization (EUA) by the FDA on November, 2020. Other monoclonal antibodies against S protein also include 80R [187] , CR3014 [188] , CR3022 [189] , and m396 [190] are under development. CR3022 is currently being tested for binding affinity to the RBD of SARS-CoV-2 S protein and showed neutralization with CR3014 combination therapy [191] , and 80R and m396 also showed potent cross-reactive neutralization in SARS-CoV [192] . Four human-original monoclonal antibodies (B5, B38, H2 and H4) from a convalescent patient showed binding to the SARS-CoV-2 RBD resulting in high neutralization [192] [193] [194] . Some studies have shown a lower mortality rate among the patients treated with convalescent plasma, compared with placebo [195] . However, treatment with convalescent plasma is limited as the therapy must be transfused, and there have been adverse effects including mild fever and allergic reactions [196] . J o u r n a l P r e -p r o o f The world has been in varying states of lockdown since March 2020, causing profound economic and social consequences. In addition, despite implementation of masks and other safety protocols, a number of lives have been lost to COVID-19. COVID-19 quickly and unexpectedly spread internationally, with millions worldwide already exposed to the virus. Some estimates indicate that between 1-20% of the population have been exposed to COVID-19; however, these estimates are questionable as many patients are asymptomatic and go untested [16] . While a few countries have considered slow and intentional exposure, akin to chicken pox parties from the 1980"s, this would need to be done safely without overburdening hospitals and would take years [95] . Additionally, SARS-CoV-2 is much more deadly than the chicken pox or influenza viruses and has shown to cause long-lasting effects on the lungs, the heart, and the central nervous system, which are still not fully understood [197] . A vaccine is desperately needed not only for individual healthcare but also to achieve herd immunity, in which at least 70% of the total population would need to be vaccinated [198] . Unfortunately, immune response to a pathogen is often heterogeneous, and varies between individuals based on age, environment, and underlying health conditions [199, 200] . While vaccines that effectively generate specific and controlled responses can allow for achieving herd immunity, chances for infections and recurring infections of SARS-CoV-2 [201] necessitate therapeutic interventions and combination therapy. Preventative vaccination is the safest and most cost-effective way to prevent COVID-19 illness and death, and the best option to combat anticipated future variants. Annually, the CDC performs surveillance on circulating strains of the influenza virus and adjusts protocols to reflect the findings in preparation of vaccines against the most prevalent strains in the coming year [202] . A J o u r n a l P r e -p r o o f similar global strategy is warranted to prevent or minimize COVID-19 and future SARS-CoV-2 variants prevalence. COVID-19 vaccines are in three broadly categorized forms of molecular, particular, and cell-based vaccines, sharing the same goal of stimulating the immune system against SARS-CoV-2 with the generation of memory cells. Molecular vaccines use whole proteins, fragmented peptides, or whole viruses and generate immune response with the aid of antigen presenting cells (APCs) such as DCs [203] . In particular, DCs play pivotal roles in capturing molecules, fragmenting them into smaller peptides, and presenting the antigenic peptides on their MHC I and II (or HLAs in humans) to prime T cells for the initiation of cellular and humoral immunity against the virus [204] . Antigen presentation by MHC I, along with co-stimulatory surface molecules such as CD80 and CD86 on DCs, leads to CD8 + T cell activation. Antigen presentation by MHC II primes CD4 + T cells which can both stimulate B cells to produce neutralizing antibodies against the pathogen and additionally assist in activation of CTLs [205] . Virus and virus-infected cells are rapidly recognized and cleared by efficiently activated immunity initiated by APCs and in collaboration with T cells and other immune cells. Most viral vaccines primarily aim to generate antibody-mediated immune response, and emerging data on T cell immunity in COVID-19 patients can guide in developing strategies for effective protection from SARS-CoV-2 [206] . Memory CD4 + T and CD8 + T cells primed against the S, N, and M proteins were detected in 100% and 70% of recovered COVID-19 patients, respectively [207, 208] , while immunization with SARS-CoV peptide-presenting DCs generated J o u r n a l P r e -p r o o f a higher number of virus-specific CD4 + T and CD8 + T cells and increased overall survival [209] . formulations showed increased immunopathological signs rather than protection [210, 211] , requiring further studies on T cell-mediated immunity by COVID-19 vaccination. Neutralizing antibody responses against SARS-CoV-2 S and N proteins have been detected in most patients within 3 weeks [212] . However, recent studies showed that CD4 + T cells in healthy individuals who have not been exposed to SARS-CoV-2 also recognized SARS-CoV-2 proteins, raising a concern of pre-existing immunity possibly contributing to antibodydependent enhancement (ADE) [213] therefore lowering B-cell stimulation. ADE is a potential challenge in the development of an effective COVID-19 vaccine, particularly via enhanced T cell-mediated immunity. When ferrets were vaccinated with modified vaccinia Ankara vaccine (MVA) that was expressing SARS-CoV S protein, increased infection by the virus [214] along with antibodies against the S protein and induced lung injury were observed in association with ADE [215] . Efficient and safe COVID-19 vaccines will need to generate desired humoral and cellular immunity against SARS-CoV-2, while simultaneously minimizing adverse side effects such as cytokine storms, and also allowing for rapid development and deployment, particularly for anticipated viral mutations. Therefore, multi-dimensional considerations of appropriate antigen selection, formulations, administration routes, and vaccination timing need to be made. including G614 and D641 [35] , although insignificant to impact on current clinical trajectories. Although the G641 mutation is sensitive to neutralization in convalescent sera, it seems to be more infectious than the D641 mutation [222, 223] . The S protein is highly glycosylated and modified glycosylation sites have been investigated to assess the infectivity and reactivity to neutralizing antibodies [119] . For example, deletion of the heavily glycosylated residues, such as N331 and N343, reduced infectivity of SARS-CoV-2, and other modifications in the RBD, A475V, L452R, V483A, and F490L, resulted in resistance to neutralizing antibodies [119] . The observation that prefusion-stabilized S protein generated more neutralizing antibodies than the native S trimer has led to multiple SARS-CoV-2 vaccine candidates [224, 225] . The RBD subunit has also been explored as a promising epitope to produce S antigen-specific neutralizing antibodies [113] . Among different S protein subunits including S1, RBD subunit, S2, and modified variants, the RBD subunit generated neutralizing antibodies at the highest tier in rabbits [226] . In addition, RBD-modified SARS-CoV-2 elicited a strong antibody response in rats [227] . cellular immunity and orchestration of other immune cells. CD4 + T and CD8 + T cells specific to the SARS-CoV-2 S, N, and M proteins can be found both in the patients who have recovered from COVID-19 and asymptomatic individuals [207] . A recent study to identify the correlation between neutralizing antibodies and CD4 + T cells against the S protein [208] suggested vital roles of CD4 + T cell activation in collaborative T and B cell activities against SARS-CoV-2. Antibody response to the N protein was developed in SARS-CoV patients [228] and its injection also elicited T cell responses in BALB/c mice [229] . However, targeting the N protein resulted in no protection from SARS-CoV, suggesting that the N protein could be a peripheral target in enhancing T cell immunity. Similar to SARS-CoV and MERS-CoV, SARS-CoV-2 prevents the development of antigen-specific T cells in order to evade immune response [230] . Both SARS-CoV and MERS-CoV replicate within double membrane vesicles to shield their viral RNA from degrading enzymes [231] and MERS-CoV downregulates genes related to antigen presentation [232] . While the mechanisms and results behind antigen presentation during SARS-CoV-2 infection remain unclear [41] , it is still important to consider tackling these immunological pathways for multi-layered protection. Overall, COVID-19 vaccines should be able to deliver the SARS-CoV-2 S protein or peptide antigen for T cell stimulation, while minimizing the delivery of other fragments that have not demonstrated assistance in generating protective immunity. Traditionally, vaccines are intramuscularly administered for sustained antigen release over time and greater likelihood of uptake and processing by APCs. However, growing evidence suggests that resident memory T cells remain present in the lung tissue and airways after the eradication of respiratory viral infections [112, [233] [234] [235] . In a mouse influenza infection model, the spleen succumbed to the disease [236] . In other studies, nasal or intramuscular vaccination with influenza antigen [237] or RSV DNA [238, 239] both generated antigen-specific memory CD8 + T cells in mice, but only nasal vaccination generated tissue-resident memory T cells that were capable of protecting the animal from a secondary exposure. For effective COVID-19 vaccination, lung-resident memory T cells should be primed against SARS-CoV-2 as they may be more effective than central and effector memory T cells [240] . Therefore, intranasal or aerosol-based inhalation could be a beneficial administration route to yield long-lasting immunity against SARS-CoV-2 [241] . This approach is being explored in the intranasal delivery of an adenovirus-based COVID-19 vaccine modified from the same platform for influenza vaccination [242] . Similar delivery routes can be easily applied to viral and nanoparticle vaccines but challenging for the delivery of cell-based vaccines. Cost and accessibility are additional indispensable considerations in determining administration routes for COVID-19 vaccines. For example, intramuscular vaccinations are typically given by professional healthcare service providers in the United States, but trained medical personnel are not as available in many countries. Access to vaccines heavily depends on their formulations which are often delicate and require storage in coolers or cryotanks, presenting challenges in transportation and cold-chain distribution [243] . An oral adenovirus based-vaccine for SARS-CoV-2 S protein has been developed in response to these challenges, offering advantages of utilizing mucosal immunity with ease of storage and needle-free applications [244] . Previous studies on SARS-CoV and MERS-CoV assisted in screening promising antigens to induce neutralizing antibodies against SARS-CoV-2 [114] . For example, SARS and MERS vaccines using the S1, RBD, and S2 subunits, showed high neutralizing antibody titers [245] . Once a desired antigen is identified, adjuvants, manufacturing process, and delivery methods need to be chosen for efficient and safe vaccination. In addition to the fast availability of the genome and structural information of SARS-CoV-2 [246] , advanced vaccine platform technology is capable of contributing to rapid vaccine development and clinical translation [32] . Alternative to conventional antigen administration, nanotechnology platforms accommodate a wide variety of antigenic moieties for vaccine delivery, attributed to their flexibility for physical or chemical modifications [247] . Nano-sized materials from natural or synthetic sources can be engineered for desired size, administration route, and targeted delivery to immune cells (e.g., APCs) to achieve both adaptive and innate immune responses [248] . COVID-19 vaccines are being developed in the form of SARS-CoV-2 proteins and subunits, nucleic acids encoding a viral antigen, live-attenuated and inactivated viruses, replicating and non-replicating viral vectors, virus-like particles, and cell-based vaccines ( Table 2 ). The immunological properties of the represented COVID-19 vaccine formulations and delivery platforms are listed in Table 3 . Epitopes of the S, M, N and E proteins have been screened to identify the immune response for enhanced antibody production and T cell responses against SARS-CoV-2 [249, 250] . Antigenicity along with structure and function of the S protein has been evaluated and the S2 subunit domain generated neutralizing antibodies against both SARS-CoV and SARS-CoV-2. Earlier vaccine studies on SARS-CoV and MERS-CoV patients using the full-length S proteins showed the presence of non-neutralizing antibodies contributing to ADE and increased systemic inflammation [251] [252] [253] . To avoid the generation of non-neutralizing antibodies, alternative subunit protein vaccines using RBD, S1, and S2 domains have been explored [113] . S2 protein subunit vaccines primed receptor binding and entry with antiviral effects. Targeting S1 protein and RBD prevented the entry to host cells thereby controlling viral infection [227] . Protein subunits have limited immunogenicity and require adjuvants in order to produce neutralizing antibodies. Whether targeting the full-length S protein or its subunits, both enhanced humoral and cellular immunity, including the generation of neutralizing antibodies [254] . Furthermore, the N protein has also been considered a promising vaccine material as it is highly immunogenic and abundantly expressed in SARS-CoV-2 [255] . T cell response against the S, M, and N subunit proteins has shown to be the most dominant and long-lasting in SARS-CoV-2 [207] , and their subunit vaccines are popularly investigated in clinical trials [256] . Trimeric SARS-CoV-2 S protein subunit vaccines can be rapidly produced by expression in mammalian cells and resemble the native trimeric viral S protein [257] , and another subunit particle of the S protein using the molecular clamp technology is undergoing clinical trials [258] (NCT04495933). Potent antigen-specific antibody responses were elicited within 2 weeks of immunization by microneedle patch to deliver S1 subunits [259] . Since the ability to elicit an immune response after injection of naked plasmid DNA was discovered, many clinical trials have used nucleic acids for vaccination against diverse diseases including infectious diseases and cancer [260, 261] . Nucleic acids are attractive vaccine J o u r n a l P r e -p r o o f candidates as they are relatively simple to produce, safe to administer, and capable of generating high immunogenicity [262, 263] . DNA vaccines are readily manufactured in large quantities, typically composed of a plasmid vector encoding a target vaccine molecule, and are capable of stimulation for long-term humoral and cellular immunity [264] . DNA is also stable and does not require cold storage, unlike conventional protein/peptide or whole virus vaccines [265] . Given the ubiquitous presence of RNase enzymes and structural differences, the half-life of DNA is longer as compared to mRNA, but DNA still needs to enter the nucleus for transcription, which may result in integration and mutation in the host genome [266] . Plasmid DNA vaccines do not elicit an appropriate immune response, requiring the need for multiple vaccinations or use of an adjuvant that promotes an increased adaptive immune response [267] . Upon expression of the transgene, and cellular immunity. Plasmid DNA vaccines expressing SARS-CoV-2 S protein generated neutralizing antibodies and antigen specific CD8 + T cells in mice and guinea pigs [268] and two repeated injections successfully protected rhesus macaques from COVID-19 [269] . Additional DNA plasmid vaccines expressing S protein are also undergoing phase I/II clinical trials (CTRI/2020/07/026352 and NCT04445389), in addition to a linear DNA vaccine against the S protein which is co-administered with alum adjuvant (N2CT04463472, NCT04527081). In contrast to earlier studies using DNA, recent studies have explored the use of S antigen-encoding mRNA for vaccination [270] . mRNA vaccines need to be delivered to the cytoplasm of the host cell for translation to the target antigenic proteins. mRNA vaccines are a promising alternative to conventional protein or whole virus vaccines, attributed to their safety, high potency for generating an immune response, and rapid and low-cost manufacturing [263] . However, instability and inefficient in vivo delivery are barriers that require improvement, and various modifications and delivery methods have aimed to increase half-life in vivo and antigen translation [271] [272] [273] . An additional hurdle shared by DNA and mRNA vaccines is the penetration to the target cells. Advancement in nucleic acid delivery has increased the potential for nucleic acid vaccines to enhance immunogenicity [263, 274] . Diverse methods have been applied for successful penetration of the lipid membrane including physical methods [275, 276] , cationic peptide delivery [277] , lipid, and polymer-based delivery [278, 279] . Lipid nanoparticles in the 100 μg-dosed group. There were no serious adverse effects but fatigue, chills, headache, myalgia, and pain at injection site were reported by some patients [270] . Phase I/II clinical trials on similar vaccines comprised of a nucleoside mRNA encoding the RBD domain or full-length S protein (NCT04449276, ISRCTN17072692, NCT04480957, NCT04368728) generated high immunogenicity with strong CD4 + T and CD8 + T cell responses [280] and similar results were also observed when injected to mice and rhesus macaques [281] . [286, 287] . One of the biggest drawbacks of Pfizer and BioNTech"s COVID-19 vaccine is long-term storage, as the vaccine must be stored at -70°C, creating challenges in reliable distribution. Despite the hurdles related to cold chain distribution, the mRNA vaccines for COVID-19 can help mitigate the global health crisis and provide an optimistic future for the application of mRNA towards preventing infectious diseases. Traditional immunization against viral infections relies on the use of the whole pathogen in a weakened or inactivated state through chemical or physical alterations, and has resulted in many clinically successful vaccinations as the most immunogenic vaccine formulations [288] . Although they are known to be effective, risk of possible mutations leading to virulence reversal and reactivation in immune-compromised individuals is a factor to consider [289] . Studies have shown that a codon change in the viral genome can reduce the virulence reversion, albeit not applicable to all viruses [290] . Coronaviruses contain non-structural proteins that are not required for replication and can be altered leading to attenuation in vivo. For example, deletion of E proteins has been used as a strategy to attenuate several zoonotic coronaviruses [289, 291, 292] . Synthetic genome code expansion (GCE) technology for site-specific incorporation of unnatural amino acids into proteins [293, 294] produced highly reproductive and genetically stable viruses with the ability to induce a robust antiviral response against MERS-CoV, and has also been applied to SARS-CoV-2 viral fragments [295, 296] . Several live-attenuated virus vaccines, including one based on a RSV platform [297] , are undergoing pre-clinical studies. Inactivated viruses have been successfully applied against polio, hepatitis A, and influenza [298] . They can be rapidly produced by propagating viruses in cell cultures such as Vero cells, followed by heat or chemical inactivation using formaldehyde or beta-propiolactone [137] . They are incapable of replication due to the destroyed RNA and are safer than liveattenuated viruses, while expressing viral epitopes that can induce antibody responses [299] . However, the replication-incapability lowers immunogenicity of inactivated viruses and requires multiple injections along with adjuvants for long-term immunity [300] . Currently, there are six vaccine candidates using inactivated viruses with an additional eight candidates undergoing preclinical studies [256] . Purified inactivated SARS-CoV-2 administered with alum adjuvant protected rhesus macaques from COVID-19 by reducing viral titers and increasing neutralizing antibodies against the S and N proteins [301] . Another genetically stable inactivated SARS-CoV-2 vaccine was successfully produced at a pilot scale and induced high levels of neutralizing antibody titers in diverse animal models after immunization on days 0 and 14 at 2µg/dose [137] . Although inactivated viruses can produce neutralizing antibodies, long-term immunity and safety needs to be further confirmed, as previous studies with inactivated SARS-CoV and RSV vaccines reported lung eosinophilia [302, 303] . Recombinant viral vectors are designed to express antigens of target pathogens and many different types of viral vectors are available [304] . Vast knowledge about the manipulation and functions of recombinant viral vectors as immunogens indicates them as highly versatile vaccine platforms [305] . Viral vectors have been engineered to deliver one or more antigens of choice, and the ability to load a relatively large genome offers the promise of developing a large variety J o u r n a l P r e -p r o o f of vaccines [306] . Delivery of target antigen by recombinant viral vectors produces potent antigens, mimicking the natural infection to induce strong T cells responses without the need for an adjuvant [307] . Rapid production additionally makes recombinant viral vectors a popular platform for vaccine delivery [304] . However, several design aspects of recombinant viral vectors need to be considered, such as potential integration into the host genome or incidental replications [308] . Non-replicating viral vectors are based on adenovirus type 5 (Ad5) and most of these vaccines are express the S protein or RBD subunit of SARS-CoV-2 [309] . However, individuals may already have pre-existing anti-adenoviral antibodies, so an alternative vector, chimpanzee adenovirus vector (ChAd) with low human prevalence, has been employed as a vaccine platform [310, 311] . Ad5 encoding SARS-CoV-2 S protein that was designed to produce neutralizing antibodies upon intramuscular injection generated toxicity at a high dose and a low dose was further evaluated in Phase II clinical trials [309, 312] . Previous phase II clinical trials of the same viral platform for an Ebola vaccine showed high initial levels of neutralizing antibodies but with rapidly declining antibody titer [313] . The majority of the volunteers in the Ebola vaccine study showed pre-existing immunity against Ad5, reducing the immunogenicity of the vaccine [314] . Ad26 encoding S protein demonstrated robust neutralizing antibody titers as its pre-existing immunity was lower than that of Ad5 [225] . This vaccine system has shown to be effective for HIV and Ebola vaccination in non-human primates and humans, respectively [315, 316] . ChAd expressing S protein is one of the most clinically advanced COVID-19 vaccines. Individuals have low pre-existing immunity to the ChAd viral backbone [316] and previous studies on MERS [317] and the tuberculosis vaccine [318] confirmed the generation of hightitered neutralizing antibodies. In SARS-CoV-2 vaccination, high levels of neutralizing J o u r n a l P r e -p r o o f antibodies [319] were detected after a single vaccination, in addition to T cell responses [319] . Additional COVID-19 vaccines based on measles virus, parainfluenza virus 5, rabies virus, and adeno-associated virus (AAV) are being developed [256] . Virus like particles (VLPs) are produced by recombinant expression of structural proteins. Successful vaccines using this platform include the hepatitis B and human papillomavirus vaccines [320, 321] . VLPs are highly stable, easy to scale up for production, and safe [322] . VLPs are structurally identical to the virus but lack the viral genome and are non-infectious. SARS-CoV-2 VLPs contain the S protein on the surface, allowing for particle fusion to host cells via the ACE2 receptor and priming using TMPRSS2 but unlike subunit vaccines, the VLPs are incapable of directly binding to B cell receptors for antibody production [323] . SARS-CoV-2 VLPs produced by expressing desired genes in mammalian cells maintained the structural and morphological properties of the virus, making VLPs a promising vaccine candidate and powerful tool for research in understanding the mechanism of SARS-CoV-2 [108] . SARS-CoV-2 VLPs produced from genetically engineered plants suggested efficacy in generation of neutralizing antibodies [324] and are undergoing phase I clinical trials (NCT04450004). VLPs comprised of hepatitis B surface antigen further engineered to carry the SARS-CoV-2 S protein on the surface are undergoing phase I clinical trials (ACTRN12620000817943). J o u r n a l P r e -p r o o f Reprogramming the immune system against infectious diseases and cancers using engineered cells has shown clinical promise in recent years and DCs are a particularly interesting immunotherapeutic target, given their ability to uptake and present antigen through various mechanisms and prime potent effector responses [325] . Apart from direct antigen presentation, DCs are characterized to migrate between lymphoid and non-lymphoid issues and modulate cytokines to control inflammation for long-lasting immunological effects [326] . Cell-based therapy has been applied to COVID-19 vaccines. In one example, a "synthetic mini-gene" Currently, education of CD4 + T, CD8 + T, and B cells against SARS-CoV-2 S protein appears to be the most feasible and attainable strategy [207] . This is the protein which has proven to be the most unique to the virus, directly permits cell infection, will best account for viral mutation over time, and generates the most consistent immune response [113, 114] . While there are many platforms being developed for vaccination, it is challenging to determine which J o u r n a l P r e -p r o o f will be most appropriate to meet all clinical demands and suitability for production and distribution in a timely manner. Viruses of choice must first be propagated in cells, isolated, and purified. For the influenza vaccine, the propagation is accomplished in fertilized chicken eggs [327] . However, SARS-CoV-2 does not replicate in chicken eggs [328] and demands an alternative scalable production method which is typically costly to develop and often requires specialized equipment. Inactivated viral and molecular vaccines contain formaldehyde used in the deactivation process, aluminum salt as an adjuvant to boost the immune response, preservatives, stabilizers, and antibiotics [329] . While whole attenuated, inactivated, and fragmented SARS-CoV-2 present simplicity in design, they also contain all the viral proteins including non-essential antigens that waste valuable space on antigen presenting machinery and decrease the yield of potent antigens [330] . Therefore, whole viruses may not be the best option for vaccination. Conventionally, antigen delivery is accomplished by administration of entire or fragmented pieces of disabled virus. While this approach has been extremely effective for vaccination against certain viruses such as influenza and polio [298] , it has not demonstrated the same efficacy for other viruses, such as HIV [331] and closely related MERS [332] . Therefore, it is possible for this approach to be ineffective for COVID-19 vaccination. Additionally, while this approach is clinically proven to be safe, inactivated viral vaccines do not typically induce longterm immunity, as evidence by the need for several doses over time [330, 333] . By vaccinating patients with the whole virus, APCs could uptake and break it down into multiple antigenic J o u r n a l P r e -p r o o f peptides for the greatest opportunity to generate an immune response, without the risk of infection [334] . Furthermore, viruses may be directly recognized by B cells for neutralizing antibody production. This vaccine platform also has the additional benefit of containing some functional RNAs, which have also proven to assist in generating immune response [335, 336] . As these viruses are limited in activity, they may only be administered to individuals with healthy, active immune systems, which excludes young children, older individuals, and anyone with underlying health conditions or undergoing immune-compromising treatments [337, 338] . SARS-CoV-2 has been particularly dangerous for the latter two groups, making the exclusion unacceptable. SARS-CoV-2 production is challenging along with other risk factors, and alternative viral vaccine platforms are being explored. For example, recombinant adenoassociated virus (AAV), used in FDA-approved gene therapies, is proven to be safe and noncarcinogenic [339] . Antigen encoding AAV can safely delivery transgenes processed by DCs for T and B cell immune responses, and recombinant AAV expressing the RBD of SARS-CoV induced sufficient S protein neutralizing antibodies [340] . Diverse delivery systems have attracted considerable attention since they can be designed to protect and deliver antigen and adjuvant payloads, and assist in multivalent antigen presentation, contributing to more effective vaccinations with enhanced immune response [341] . Advances in nanotechnology offer great potential in vaccine design and have helped in development of novel candidate vaccine formulations at unprecedented speed [32] . Vaccine carriers capable of controlled release, such as polymer matrixes and hydrogels, or newly J o u r n a l P r e -p r o o f developed nanotechnology platforms with desirable physical, chemical, and biological properties are promising for the targeted delivery of antigens and the prevention of disease transmission. Production of nanoparticle-based vaccines heavily depends on the materials (polymer, protein, lipids, and cellular vesicles) and the payload (peptide, protein, RNA, DNA, and whole virus) of choice. In this case, a scalable amount of SARS-CoV-2 vaccine payload will need to be readily available. This will entail the mass biological production of viruses and S protein, or synthesis of the S protein and/or peptides. Large-scale production of nucleic acid vaccine payloads may be more achievable than viruses and antigenic proteins, as these can be collected from small batches and amplified [342] . Like their molecular counterparts, nanoparticle vaccines often require co-administration or co-encapsulation of an adjuvant for efficient DC stimulation. Co-encapsulation ensures the adjuvant and the antigenic payload reach the target site at the same time, which is critical for DC antigen processing and maturation [343] . Nanoparticle vaccine formulation is advantageous over administrating molecular vaccines alone because the payload is protected from immature degradation and unintended targets such as macrophages. Furthermore, recent progress has allowed for the preparation of nanoparticles with desired physiochemical properties including size, shape, solubility, hydrophilicity, hydrophobicity, and surface modification, making them highly tunable for vaccine delivery [344, 345] . Additionally, refrigerated storage is not necessary for lyophilized nanoparticles. Nanoparticle-based formulations may increase uptake by phagocytic APCs, particularly when targeting moieties are incorporated on their surface [346] . Co-delivery of adjuvant makes APC-targeting nanoparticles ideal vaccines for efficiently and properly educating T and B cells including high antibody production [343] . Chitosan and dextran sulfate-based polymeric nanoparticles, inorganic nanoparticles such as AuNPs, and carbon nanotubes have been exploited for vaccination [347] . Poly lactic-co-glycolic-acid (PLGA) nanoparticles are suitable for encapsulating antigens for controlled release and induced prolonged cellular and humoral immunity [348] . LNPs are promising carriers for mRNA vaccines due to their ability to efficiently deliver payloads into the cytoplasm of a target cell via parenteral administration and subsequently generate high-titered antibodies and enhanced T cell immunity [263] . IgG production, IgA production, neutralizing antibodies, CD4+ T cell activation, CD8+ T cell activation, production of memory CD8+ T cells [352, [360] [361] [362] The aforementioned vaccines require co-delivery of adjuvants for proper immune stimulation and response [349] . Adjuvants are natural or synthetic materials that are readily recognized by the immune system and enhance the desired immune response [350] . or antigenic proteins or peptides will likely require addition of adjuvants [349, 354] . With the rapid evolution of COVID-19 vaccines, roles and necessities of adjuvants for desired immunity will be elucidated and result in optimal formulations. Patient-isolated DCs by leukapheresis are used for personalized cell therapy for cancer [326] . While clinical trials demonstrated safety and increase of survival of the patients, DC therapy has not come to fruition due to multiple challenges related to time-consuming and laborintensive preparation, limited scalability, and difficulty controlling DC maturation state which dictates how and at what magnitude the immune system responds [325] . Despite "off the shelf" versions of DCs and allogenic and HLA-matching DCs which are readily available, DC therapy is still under exploration [363] . DCs need to be pulsed with proteins, peptides, or viruses for antigen presentation along with appropriate stimulations [364] . If a rapid and reliable production J o u r n a l P r e -p r o o f Journal Pre-proof of SARS-CoV-2 antigenic peptides was available, DCs could be directly incubated with the peptides for size-restricted presentation by MHC I and II [365] . Immune cells are designed with inherent plasticity to respond to microenvironmental and temporal cues, which is beneficial for immune activation when they are at desired states. For example, DC-based COVID-19 vaccines may require pre-conditioning to a stable mature state and active migration to lymph nodes [325, 366] . Furthermore, DC-based vaccine formulations are typically difficult to quality check, attributed to batch to batch variation, especially before and after freezing and thawing. [367] . The access to cell-based vaccines are limited due to high production cost, stringent storage and transport requirements, and limited availability [367] . barriers, such as clearance associated with molecular and viral vaccines, and the cell recruitment steps required by other vaccination methods. Activated DCs migrate through the lymphatics to the lymph node where they can educate T and B cells for active clearance of infected cells and antibody production. In order to protect the majority of global populations, including high-risk groups, more vaccines as already demonstrated by the current clinical trials [26, 32] . A significant challenge in COVID-19 vaccine development is frequent mutations in the SARS-CoV-2 S protein, the most common target antigen in the current effort, limiting the efficacy of the first generation COVID-19 vaccines and even requiring the recovered patients to be vaccinated against new mutants [35, 119, 222] . Therefore, an ideal COVID-19 vaccine platform must allow easy and rapid accommodation of newly mutated and identified antigens. The current ongoing pre-clinical and Inflammation is an essential part of immune response and required to eliminate pathogens, followed by tissue regeneration and homeostasis restoration [368] . In contrast to other infections where inflammatory activity is beneficial, excessive production of cytokines/chemokines during SARS-CoV-2 infection, called the cytokine storm, leads to ARDS or multiple-organ dysfunction [99, 103] . Controlling the activity of cytokines/chemokines in the early stages of COVID-19 using immunomodulators, cytokine antagonists, and reduction of inflammatory cell infiltration to the site of inflammation is reported to help reduce patient mortality rates [76, 103, 369] . As combined drug therapy offers lowered dosage, reducing the side effects, and the likelihood of developing drug resistance [370] , COVID-19 vaccines using a nanotechnology platform are able to co-deliver antigens and additional desired drugs such as protease inhibitors, reverse transcriptase inhibitors (e.g., remdesivir), and immune suppressants (e.g., dexamethasone) to prevent a cytokine storm [371] or synergistically eradicate SARS-CoV-2 before severe disease J o u r n a l P r e -p r o o f progression (Figure 7) . Nanoparticles with cytokine-binding properties quenched the cytokine storm, and PEGylated dextran-coated super magnetic iron oxide nanoparticles (SPION) tethered with anti-IL4Rα antibodies decreased pro-inflammatory cytokine expression and repaired lung tissue in mice [372] . ACE2-expressing CD68 + CD169 + macrophages that contain the SARS-CoV-2 N protein increased IL-6 in spleen and lymph nodes [373] , and using nanoparticles that target the inflammatory cells responsible for cytokine storm is a promising approach to developing efficient and safe COVID-19 vaccines. Recent studies showed biomimetic nanomaterials such as extracellular vesicles (EVs) carrying anti-inflammatory drugs to calm the local cytokine release syndrome in pneumonic lungs [374] . Furthermore, ACE2-and CD147expressing cellular nanosponges were found to bind and inhibit SARS-CoV-2 infection [375] . While the extremely unusual circumstance requiring immediate production and J o u r n a l P r e -p r o o f availability of COVID-19 vaccines has led the leading candidates to advanced clinical stages at remarkable paces, robust clinical assessment on potential risks must be made and considered before vaccination to unprecedently large populations [32, 58, 240] . While still relatively rare, some patients in clinical trials experienced serious side effects that were not fully explained [376] . Re-opening of communities and countries based on the release of ineffective or partially effective vaccines could have dire impacts as also indicated by the FDA"s requirements for rigorous trials before vaccine approval [377] . A premature statement could have unintended consequences, such as the unproven promise of hydroxychloroquine in COVID-19 treatment that led to a shortage for Lupus patients [378] . The efficacy and durability of immunity by COVID-19 vaccines are unknown and may require a two-dose heterogeneous prime-boost strategy or a periodic booster dose [379, 380] . Pre-existing antibodies against SARS-CoV-2 or other viruses and their cross-reactivity may also play roles in efficacy and safety of COVID-19 vaccines [207] but having individuals checked before vaccination could be helpful but a daunting task. Controlling both virus replication and inflammation can help reduce patient mortality rate but their clinical efficacy is limited. Diverse nanotechnology platforms can be designed for combination therapy by the delivery of multivalent antigens and desired drugs which can synergistically reduce viral load, inflammation, and severe disease progression. Cultivation of a Novel Type of Common-Cold Virus in Organ Cultures Origin and evolution of pathogenic coronaviruses Human Coronavirus-229E,-OC43,-NL63, and-HKU1, Reference Module in Life Sciences Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections Aerosol emission of child voices during speaking, singing and shouting Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice It is time to address airborne transmission of COVID-19 Aerosol transmission of SARS-CoV-2? Evidence, prevention and control Probable Evidence of Fecal Aerosol Transmission of SARS-CoV-2 in a High-Rise Building Evidence of airborne transmission of the severe acute respiratory syndrome virus Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review A pneumonia outbreak associated with a new coronavirus of probable bat origin Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application Immune-mediated approaches against COVID-19 The trinity of COVID-19: immunity, inflammation and intervention Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) The contribution of vaccination to global health: past, present and future CDC 2020-2021 Flu Vaccine Campaign Kickoff The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness Next-generation vaccine platforms for COVID-19 A materials-science perspective on tackling COVID-19 Insights from nanotechnology in COVID-19 treatment COVID-19 Vaccine Frontrunners and Their Nanotechnology Design Why Go NANO on COVID-19 Pandemic? Nanomedicine and the COVID-19 vaccines Developing Covid-19 vaccines at pandemic speed Whither COVID-19 vaccines? The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity, bioRxiv Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus Structure, function, and evolution of coronavirus spike proteins Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response Coronavirus envelope protein: current knowledge Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cell entry mechanisms of SARS-CoV-2 SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues Single-cell RNA expression profiling shows that ACE2, the putative receptor of Wuhan 2019-nCoV, has significant expression in the nasal, mouth, lung and colon tissues, and tends to be co-expressed with HLA-DRB1 in the four tissues SARS-CoV-2 invades host cells via a novel route: CD147-spike protein Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4 Middle East respiratory syndrome-coronavirus infection into established hDDP4-transgenic mice accelerates lung damage via activation of the pro-inflammatory response and pulmonary fibrosis Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26 Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2 Nanotechnology for COVID-19: therapeutics and vaccine research Coronaviruses pandemics: Can neutralizing antibodies help? A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes SARS-CoV-2 Vaccines: Status Report Innate Immunity of the Lung: From Basic Mechanisms to Translational Medicine The innate immune function of airway epithelial cells in inflammatory lung disease Cellular immune reactions in the lung Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic SARS-CoV-2 infection-induced immune responses: Friends or foes? Alveolar macrophages: plasticity in a tissue-specific context Differential roles of lung dendritic cell subsets against respiratory virus infection Tissue-resident dendritic cells and diseases involving dendritic cell malfunction Influenza virusspecific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination T Follicular Helper Cell Biology: A Decade of Discovery and Diseases Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza Host Immune Response to Influenza A Virus Infection Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus, bioRxiv SARS-CoV-2 infection: The role of cytokines in COVID-19 disease COVID-19: immunopathogenesis and Immunotherapeutics SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes Human coronaviruses: a review of virus-host interactions Interferon-stimulated genes: a complex web of host defenses Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum Expression and Cleavage of Middle East Respiratory Syndrome Coronavirus Polyprotein Induce the Formation of Double-Membrane Vesicles That Mimic Those Associated with Coronaviral RNA Replication, mBio Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3 Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6 Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists Hidden immune weakness found in 14% of gravely ill COVID-19 patients Pathogenesis of COVID-19 from a cell biology perspective SARS-CoV-2 viral load predicts COVID-19 mortality Virological assessment of hospitalized patients with COVID-2019 Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention Impaired Cytotoxic CD8(+) T Cell Response in Elderly COVID-19 Patients Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome Cytokine storm syndrome in coronavirus disease 2019: A narrative review The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Dysregulation of Immune Response in Patients With Coronavirus Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet CT Manifestations of Two Cases of 2019 Novel Coronavirus (2019-nCoV) Pneumonia Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) The emerging role of resident memory T cells in protective immunity and inflammatory disease Skin infection generates non-migratory memory CD8+ T RM cells providing global skin immunity Mucosal resident memory CD4 T cells in protection and immunopathology Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Antibody responses against SARS-CoV-2 in COVID-19 patients Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia SARS-CoV-2 neutralizing antibody development strategies From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19 Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19 Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review Drug Administration, Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Rapid review for the anti-coronavirus effect of remdesivir Development of an inactivated vaccine candidate for SARS-CoV-2 Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase An Update on Current Therapeutic Drugs Treating COVID-19 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Clinical trials on drug repositioning for COVID-19 treatment Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors Prosper, Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro Antiviral and antiinflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Hydroxychloroquine: An old drug with new relevance Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Drug Administration, Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine Positive RT-PCR Test Results in Patients Recovered From COVID-19 Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19 Immunomodulation in COVID-19 Interleukin-6 in COVID-19: a systematic review and metaanalysis Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome Effective treatment of severe COVID-19 patients with tocilizumab Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: 'Correspondence on: 'Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study' by Della-Torre et al' by Cheng and Zhang JAK inhibition as a therapeutic strategy for immune and inflammatory diseases Baricitinib as potential treatment for 2019-nCoV acute respiratory disease The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 Association between Administration of Systemic Corticosteroids and Mortality among critically ill patients with COVID-19: a meta-analysis Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic Use of corticosteroids in influenza-associated acute respiratory distress syndrome and severe pneumonia: a systemic review and meta-analysis Blood Institute Acute Respiratory Distress Syndrome Clinical Trials, Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report Dexamethasone nanomedicines for COVID-19 Roles of natural killer cells in antiviral immunity Cellular immune responses to severe acute respiratory syndrome coronavirus Natural killer cell immunotypes related to COVID-19 disease severity Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19 Mesenchymal stem cell perspective: cell biology to clinical progress Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment Systematic identification of factors for provirus silencing in embryonic stem cells Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study Convalescent plasma in Covid-19: Possible mechanisms of action Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 US Food and Drug Administration, Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants Potent crossreactive neutralization of SARS coronavirus isolates by human monoclonal antibodies Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants Monoclonal Antibody as a Potential Anti-COVID-19 A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody Effectiveness of convalescent plasma therapy in severe COVID-19 patients Convalescent Plasma to Treat COVID-19: Possibilities and Challenges Potential neurological effects of severe COVID-19 infection COVID-19 herd immunity: where are we? Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature Agedependent effects in the transmission and control of COVID-19 epidemics Genomic evidence for reinfection with SARS-CoV-2: a case study Selecting Viruses for the Seasonal Influenza Vaccine Peptide Vaccine: Progress and Challenges, Vaccines (Basel) Present Yourself! By MHC Class I and MHC Class II Molecules CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function T cell responses in patients with COVID-19 Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Oxford Immunology Network Covid-19 Response, I.C. Investigators A mouse-adapted SARScoronavirus causes disease and mortality in BALB/c mice Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2 A perspective on potential antibody-dependent enhancement of SARS-CoV-2 Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection Human leukocyte antigen susceptibility map for SARS-CoV-2 Progress and prospects on vaccine development against SARS-CoV-2, Vaccines Mutations in the Coronavirus Spike Protein Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates Host Immune Response and Immunobiology of Human SARS-CoV-2 Infection Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections Lung niches for the generation and maintenance of tissue-resident memory T cells Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection Airway-Resident Memory CD8 T Cells Provide Antigen-Specific Protection against Respiratory Virus Challenge through Rapid IFN-gamma Production Airway T cells protect against RSV infection in the absence of antibody Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung Immunological considerations for COVID-19 vaccine strategies Heuze-Vourc'h, Inhalation of Immuno-Therapeutics/-Prophylactics to Fight Respiratory Tract Infections: An Appropriate Drug at the Right Place! Safety and Immunogenicity of NasoVAX, a Novel Intranasal Influenza Vaccine: 2554, Open Forum Infectious Diseases Cold chain transportation decision in the vaccine supply chain Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection, bioRxiv A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health Nanoparticle formulated vaccines: opportunities and challenges Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines Correction: Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Nonhuman Primates Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development World Health Organization, DRAFT landscape of COVID-19 candidate vaccines Author Correction: Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo Artificial molecular clamp: a novel device for synthetic polymerases Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development Cancer DNA vaccines: current preclinical and clinical developments and future perspectives Advances in mRNA vaccines for infectious diseases The past, current and future trends in DNA vaccine immunisations mRNA vaccines -a new era in vaccinology DNA vaccines: a key for inducing long-term cellular immunity DNA vaccines: ready for prime time? A comparison of plasmid DNA and mrna as vaccine technologies, Vaccines DNA Vaccines-How Far From Clinical Use? Immunogenicity of a DNA vaccine candidate for COVID-19 DNA vaccine protection against SARS-CoV-2 in rhesus macaques m, An mRNA Vaccine against SARS-CoV-2 -Preliminary Report Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability Materials for non-viral intracellular delivery of messenger RNA therapeutics Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity Intradermal electroporation of naked replicon RNA elicits strong immune responses Electroporation-enhanced gene delivery in mammary tumors Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates, bioRxiv Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study Pfizer and BioNTech achieve first authorization in the world for a vaccine to combat covid-19 Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination History of vaccination Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine Evolutionary reversion of live viral vaccines: Can genetic engineering subdue it? Deletion of both the tyrosine-based endocytosis signal and the endoplasmic reticulum retrieval signal in the cytoplasmic tail of spike protein attenuates porcine epidemic diarrhea virus in pigs Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein Generation of influenza A viruses as live but replication-incompetent virus vaccines Synthesis at the interface of virology and genetic code expansion Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform, bioRxiv An infectious cDNA clone of SARS-CoV-2 A recombinant respiratory syncytial virus vaccine candidate attenuated by a low-fusion F protein is immunogenic and protective against challenge in cotton rats Vaccine analysis: strategies, principles, and control Site-specific glycan analysis of the SARS-CoV-2 spike Rationalizing the development of live attenuated virus vaccines Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2 Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus Viral vectors for vaccine applications Developments in Viral Vector-Based Vaccines, Vaccines (Basel) Engineering targeted viral vectors for gene therapy Novel viral vectors in infectious diseases Immune Responses to Viral Gene Therapy Vectors Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model, npj Vaccines Development of novel vaccine vectors: Chimpanzee adenoviral vectors Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26. ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, nonrandomised, uncontrolled, phase 1 trial, The Lancet Infectious Diseases A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime-MVA85A boost in healthy UK adults Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind Virus-like particles for the prevention of human papillomavirusassociated malignancies A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice Virus-like particle vaccines: immunology and formulation for clinical translation Advances and challenges in enveloped virus-like particle (VLP)-based vaccines Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules Dendritic cell-based immunotherapy Engineering dendritic cell vaccines to improve cancer immunotherapy Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing SARS-CoV-2 does not replicate in embryonated hen"s eggs or in MDCK cell lines Vaccine Adjuvants: from 1920 to 2015 and Beyond, Vaccines (Basel) Immunological mechanisms of vaccination Challenges in the development of an HIV-1 vaccine Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus How advances in immunology provide insight into improving vaccine efficacy Novel antigen delivery systems Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives Live attenuated versus inactivated influenza vaccine in infants and young children Engineering adeno-associated virus vectors for gene therapy Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines Correction: Review: a comprehensive summary of a decade development of the recombinase polymerase amplification Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines? Nanoparticle Vaccines Against Infectious Diseases, Front Immunol Nanoparticle-based vaccines: opportunities and limitations, Nanopharmaceuticals, Elsevier2020 Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice Adjuvants for Coronavirus Vaccines Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848 Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study Dendritic cells based immunotherapy The ins and outs of MHC class II-mediated antigen processing and presentation Dendritic cell migration in health and disease Dendritic cell-based vaccines: barriers and opportunities Overview of the immune response Therapeutic siRNA silencing in inflammatory monocytes in mice Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research A novel anti-IL4Ralpha nanoparticle efficiently controls lung inflammation during asthma The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes Calming the Cytokine Storm in Pneumonia by Biomimetic Nanoparticles Cellular nanosponges inhibit SARS-CoV-2 infectivity Treatments in the COVID-19 pandemic: an update on clinical trials Warp Speed" operations in the COVID-19 pandemic: moving too quickly? Potential shortages of hydroxychloroquine for patients with lupus during the coronavirus disease 2019 pandemic SARS-CoV-2 Vaccine Development: Current Status Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine